In metastatic breast and prostate cancer patients, RANKLi have been shown to directly influence both primary and secondary tumorigenesis through NFkB inhibition, leading to decreased tumor growth and lower SRE rates in patients receiving RANKLi compared to those receiving BPs [20]. Here, NFKB1 is linked to prostate cancer.